Video

Arrhythmia & Electrophysiology Round Table 5 - AF Ablation: Part 1

Published: 10 Dec 2020

  • Views:

    Views Icon 115
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

In the fifth in the series of videos to mark the launch of Arrhythmia & Electrophysiology Review, RadcliffeCardiology.com in association with the EHRA and doctors.net.uk, presents Arrhythmia & Electrophysiology Round Table - 5: AF Ablation Part 1. In this video, the Round Table asks ‘Could ablation be the first line therapy for paroxysmal AF?’

The Round Table discusses treatment approaches available to the arrhythmologists to achieve the best patient outcomes in atrial fibrillation, with insightful opinions expressed on both the role of catheter ablation and various drug options.

The Arrhythmia & Electrophysiology Round Table event and videos were supported by an unrestricted grant from Biosense Webster. The view and opinions expressed are those of the attendees, and not necessarily of Biosense Webster.

 

Round Table Participants

 

  • Angelo Auricchio, Fondazione Cardiocentro Ticino, Lugano, Switzerland
  • Hein Heidbuchel, University Hospital Gasthuisberg, Leuven, Belgium
  • Gerhard Hindricks, Heart Center Leipzig, Germany
  • Josef Kautzner, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
  • Pier Lambiase, Heart Hospital, University College London, United Kingdom
  • Mark O'Neill, St Thomas’ Hospital and King’s College London, United Kingdom
  • Richard Schilling, St Bartholomew’s and The Royal London Hospital, United Kingdom

 

Also from the series...

 

Publishing throughout 2013 from the Arrhythmia & Electrophysiology Round Table:

  • Approaches to Ablation – Part 1: New Technologies in Ablation
  • Approaches to Ablation – Part 2: Radioprotection
  • Atrial Fibrillation: Rate versus Rhythm
  • AF Ablation – Part 1: Could ablation be the first line therapy for paroxysmal AF?
  • AF Ablation – Part 2: Follow-up issues with patients with atrial fibrillation
  • Risk stratification – Part 1
  • Risk stratification – Part 2: RT non-responders
  • Closing Remarks and Summaries